LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Kymera Therapeutics Inc

Cerrado

SectorSalud

47.81 0.57

Resumen

Variación precio

24h

Actual

Mínimo

46.89

Máximo

49.62

Métricas clave

By Trading Economics

Ingresos

5.2M

-66M

Ventas

15M

22M

BPA

-0.82

Margen de beneficio

-296.747

Empleados

208

EBITDA

-5.7M

-74M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+26.94% upside

Dividendos

By Dow Jones

Próximas Ganancias

7 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

622M

2.8B

Apertura anterior

47.24

Cierre anterior

47.81

Noticias sobre sentimiento de mercado

By Acuity

34%

66%

95 / 380 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

Kymera Therapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

1 nov 2024, 03:00 UTC

Principales Noticias

U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners -- WSJ

9 jul 2024, 09:05 UTC

Principales Noticias

These Stocks Are Moving the Most Today: Tesla, Corning, BP, Intel, and More -- Barrons.com

Comparación entre iguales

Cambio de precio

Kymera Therapeutics Inc Esperado

Precio Objetivo

By TipRanks

26.94% repunte

Estimación a 12 meses

Media 60.5 USD  26.94%

Máximo 79 USD

Mínimo 51 USD

De acuerdo con 15 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Kymera Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

15 ratings

15

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

28.34 / 33.56Soporte y Resistencia

Corto Plazo

Weak Bullish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

95 / 380 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Kymera Therapeutics Inc

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.